Previous Article | Next Article 
Clinical and Diagnostic Laboratory Immunology, January 1998, p. 50-57, Vol. 5, No. 1
1071-412X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Expression, Structure, and Location of Epitopes of
the Major Surface Glycoprotein of Pneumocystis carinii f.
sp. carinii
Michael J.
Linke,1,2,*
Susan M.
Sunkin,3
Ryan P.
Andrews,1
James R.
Stringer,3 and
Peter
D.
Walzer1,2
Cincinnati Veterans Affairs Medical
Center,1
Department of Internal
Medicine, University of Cincinnati College of
Medicine,2 and
Department of Molecular
Genetics, Biochemistry, and Microbiology, University of Cincinnati
College of Medicine,3 Cincinnati, Ohio
Received 29 May 1997/Returned for modification 31 July
1997/Accepted 2 October 1997
 |
ABSTRACT |
The major surface glycoprotein (MSG) of Pneumocystis
carinii f. sp. carinii consists of a heterogeneous
family of proteins that are encoded by approximately 100 unique genes.
A genomic expression library was screened with a panel of MSG-specific
monoclonal antibodies (MAbs) to identify conserved and rare epitopes.
All of the antibodies reacted with epitopes that are encoded within the
5' end of MSG. The results from the expression screening identified antibodies that recognize highly conserved, moderately conserved, and
rare epitopes. Four MAbs (MAbs RA-F1, RA-E7, RA-G10, and RB-E3) reacted
with a maltose binding protein-MSG-B fusion protein
(MBPMSG-B41-1065) by immunoblotting and
enzyme-linked immunosorbent assay. Three of the MAbs (MAbs RA-F1,
RA-G10, and RA-E7) reacted with the same continuous epitope that was
localized to amino acids 278 to 290 of MSG-B. Comparison of the
sequence of the RA-F1-, RA-G10-, and RA-E7-reactive epitope to the
deduced amino acid sequences of multiple MSGs demonstrated that it is
highly conserved. The reactivity of RB-E3 with MSG-B was shown to be
dependent on amino acids 184 to 192, which may comprise a portion of a
discontinuous epitope.
 |
INTRODUCTION |
Pneumocystis carinii f.
sp. hominis is an important cause of pneumonia in patients
with human immunodeficiency virus infection, cancer, and organ
transplantation and in other immunocompromised hosts. The host factors
that predispose individuals to the development of P. carinii
f. sp. hominis pneumonia involve impaired cellular and
humoral immunity; however, the specific immune defects are poorly
understood. All forms of P. carinii that have been examined contain a 95,000- to 140,000-kDa glycoprotein, termed either the major
surface glycoprotein (MSG) or glycoprotein A (gpA), which plays an
important role in the immunobiology of the organism (12, 17, 20,
34, 42, 50). MSG is highly immunogenic and stimulates the
production of various cytokines, contains protective B- and T-cell
epitopes, and facilitates the interaction of P. carinii with
host cells (9, 30, 33, 43, 44, 54).
MSG actually consists of a heterogeneous family of proteins encoded by
about 100 genes. DNA sequence analysis of MSG cDNAs and/or genes has
demonstrated that the gene family encodes many distinct MSG isoforms,
which are very similar in size but whose sequences vary (10, 18,
21, 26, 48).
Transcription of MSG genes appears to occur only within a single
telomeric expression site (7, 39, 49). The isolation of
multiple unique MSG cDNAs from a single P. carinii f. sp.
carinii-infected rat lung suggests that multiple MSG mRNAs
and proteins may be present at the same time within a population of
P. carinii f. sp. carinii (26). The
ability to alter the expression of different MSG molecules raises the
possibility of antigenic variation occurring in P. carinii
f. sp. carinii.
MSG appears to be involved in both the cellular and the humoral immune
responses of the host to P. carinii f. sp.
carinii. Spleen cells isolated from rats environmentally
exposed to P. carinii f. sp. carinii proliferate
in response to MSG, and sera from these animals contain MSG-specific
antibodies (44). MSG is also recognized by humans exposed to
P. carinii f. sp. hominis. MSG-specific
antibodies have been detected in approximately 30 to 70% of human
serum specimens that contain P. carinii f. sp. hominis antibodies (28, 31). Animals generate a
vigorous immune response against MSG upon immunization with purified
antigens or P. carinii f. sp. carinii
preparations (7). Passive immunotherapy with MSG-specific
monoclonal antibodies (MAbs) and/or hyperimmune polyclonal antiserum
has also been shown to modulate P. carinii infection in
ferrets, rats, and mice with severe combined immunodeficiency, supporting the significance of MSG in the host response to P. carinii (13, 14, 35). The involvement of MSG in the
host immune response suggests that immunization with it may provide protection against P. carinii infection. Because multiple
isoforms of MSG can be expressed within a population of P. carinii, it will be important to identify immunoreactive regions
common to all MSGs.
Several groups have described the production and characterization of
P. carinii-specific MAbs (11, 16, 19, 23, 24, 27,
29). MSG-specific MAbs have also used to distinguish rat P. carinii f. sp. carinii and P. carinii f. sp.
ratti strains at a phenotypic level (47). A MAb
specific to MSG purified from P. carinii f. sp.
hominis has been used in the development of a new method of
diagnosis of P. carinii f. sp. hominis pneumonia by radioimmunodetection (15).
In the study described in this paper we have characterized a panel of
MSG-specific MAbs on the basis of the frequency with which their
epitopes are encoded and expressed within a population of P. carinii f. sp. carinii. This analysis demonstrated the
presence of conserved epitopes that appear to be present on the
majority of MSGs and epitopes that appear to be present on a restricted number of MSGs. A single MSG isoform was expressed in a bacterial vector and was used to identify the epitopes recognized by two of the
MAbs that recognize conserved epitopes. Detailed characterization of
MSG-specific MAb reactivities and identification of epitopes recognized
by the MAbs will greatly improve their usefulness in the analysis of
the expression of different MSG isoforms.
 |
MATERIALS AND METHODS |
Pneumocystis nomenclature.
The
Pneumocystis nomenclature proposed at the 3rd International
Workshop on Pneumocystis in Cleveland, Ohio, in June 1994 will be used in this report (32). Provisional tripartite
names denoting the mammal of origin were given to the organism
populations isolated from various mammalian hosts.
Pneumocystis isolated from rats will be referred to as
either P. carinii f. sp. carinii, designated the
prototype, or P. carinii f. sp. ratti, designated a variant; the organism from human beings will be referred to as
P. carinii f. sp. hominis.
Source of organisms.
P. carinii f. sp.
carinii pneumonia was induced by corticosteroid treatment of
rats, and the organisms were recovered from infected lungs and were
quantitated as described previously (4). Briefly, infected
lungs were removed en bloc, minced, and homogenized. The homogenate was
centrifuged at 1,000 × g for 10 min at 4°C, and the
resulting pellet was treated with 0.85% ammonium chloride to lyse the
erythrocytes. The pellet was washed twice, and the organisms were
resuspended in phosphate-buffered saline.
Source of antibodies.
MSG-specific MAbs were produced and
characterized as described previously (27). Three different
P. carinii antigen preparations were used to produce the
MAbs used in this study: (i) P. carinii f. sp.
carinii, (ii) MSG purified from P. carinii f. sp.
carinii, and (iii) detergent-solubilized P. carinii f. sp. hominis (Table 1). Mice were immunized three times
subcutaneously with the antigen preparations, and antigen preparations
were then injected intraperitoneally 3 days prior to fusion. Spleen
cells from the mice were fused to a myeloma cell line, and hybrids were
selected by previously described methods. The resulting hybridomas were
screened for P. carinii-specific reactivity by
immunoblotting or enzyme-linked immunosorbent assay (ELISA). Polyclonal
antibodies to P. carinii f. sp. carinii MSG were
prepared by immunizing rabbits with purified MSG. Polyclonal rabbit
anti-maltose binding protein (anti-MBP) serum was obtained from New
England Biolabs, Beverly, Mass. Enzyme-conjugated antibodies were
obtained from Kirkegaard & Perry, Gaithersburg, Md.
Hybridization and screening of the
gt11 genomic expression
library.
The bacteriophage
gt11 genomic library was generated
by insertion of randomly sheared P. carinii f. sp.
carinii DNA into
gt11, and hybridizations were performed
by standard methods (36). The
gt11 library was screened
with MAbs as described previously (10). To determine the
number of plaques to be screened, the library was first evaluated by
hybridization of the
gt11 library to four different single-copy gene
probes and to an MSG gene probe. The single-copy gene probes used were
the TATA box binding protein (40), thymidylate synthase
(8), alpha-tubulin (53), and 55-kDa antigen
(37). Approximately 20,000 plaques were screened with each
gene probe. Four positive plaques were detected with the 55-kDa antigen
gene probe, and five positive plaques were found with the other gene
probes. These data suggested that 4,000 to 5,000 plaques contain one
genome equivalent in this library. This is reasonably close to the
theoretical value calculated from the size of the genome, which is
approximately 107 bp (5). A genome of this size
would be contained in 4 × 103 phages, each carrying a
2.5-kb insert. The
gt11 library was generated with randomly sheared
P. carinii f. sp. carinii DNA that ranged in size
from 1 to 4 kb.
Analysis of MAb RA-F1-reactive
gt11 clones.
Four clones
reactive with MAb RA-F1 were plaque purified by standard techniques
(36). The reactivities of each of these clones were
determined with the other MAbs as described previously. Phage DNA from
all four clones was isolated by the Wizard lambda prep kit (Promega,
Madison, Wis.). Partial sequences from both insert ends were obtained
by using a PCR sequencing kit with the
gt11 forward and reverse
primers by following the manufacturer's standard protocol (Life
Technologies, Inc., Gaithersburg, Md.). The sequences from each clone
were aligned with the DNANALYZE program (51) to MSG-B
(41) to determine the location of the beginning and end of
each of the inserts. Primer C5 (5'-CATGAAAGACTTGAGAAATGT-3') was used in the PCR cycle sequencing of clones 1 and 4 in order to compare sequences from the same area from all four RA-F1-reactive clones.
The epitope regions of clones 1 and 3 were amplified with primers C3
(5'-GTAACATCCTTCCCTCAAC-3') and C7
(5'-GTCTTGTCCCTTTTTATAGCA-3'), and the epitope regions of
clones 2 and 4 were amplified with primers C5.2
(5'-TAGTCCTGTCAAGCCGA-3') and C7. The products were ligated
into pGemT (Promega) according to the manufacturer's instructions, and
the inserts were sequenced by the DNA core facility of the Department
of Molecular Genetics, Biochemistry, and Microbiology, University of
Cincinnati College of Medicine.
Cloning of the msg-b gene.
A gene encoding a
single species of MSG, designated msg-b, was amplified from
Rp3-1 template DNA; Rp3-1 is a 16-kb fragment containing repetitive
elements cloned from the P. carinii f. sp. carinii genome (38, 39, 41). Primers
msg1+ and msg3801
(Table
2) were designed to amplify the entire
msg-b gene. MunI sites were engineered into these
primers in order to ligate the products directly into an
EcoRI site. PCR was performed by standard methods. Reactions
were amplified for two cycles of 94°C for 1 min, 45°C for 1 min,
and 72°C for 3 min and were then amplified for 30 cycles of 94°C
for 1 min, 50°C for 1 min, and 72°C for 3 min. Amplified DNA was
purified by using the Wizard PCR Preps system (Promega) according to
the manufacturer's instructions. Ligation of the MunI-cut
msg-b PCR product into the EcoRI site of pMALc2
was unsuccessful. Therefore, restriction sites that were compatible
with sites in the pMALc2 polylinker were identified within the
msg-b sequence. Digestion of an AvaI site present
at base 124 and a HindIII site located downstream of the
stop codon at base 3366 allowed ligation of the msg-b PCR
product between the SalI and HindIII sites of
the pMALc2 polylinker. This construct, designated
pMAL/msg-b123-3366, contains the entire msg-b gene lacking the initial 122 bp ligated in frame with the MBP that is
encoded by pMALc2.
Exonuclease digestion-generated MSG-B truncations.
In order
to produce a linear construct with 5' and 3' 4-base overhanging ends, a
24-bp oligonucleotide containing a KpnI site was cloned into
the 3' end of the pMAL/msg-b123-3366 construct. After
digestion with KpnI and SalI (Promega), the
linearized DNA was subjected to unidirectional digestion with
exonuclease III (ExoIII; New England Biolabs) as described previously
(2, 6).
Amplification and cloning of internal msg-b
fragments.
Eight overlapping MBPMSG-B fusion proteins
were produced by amplifying the target regions of msg-b by
PCR and cloning the products into pMAL-c2. Primers were either
constructed to correspond to flanking regions of the target MSG-B
region or to sequences within pMAL-c2 (Table 2). PCR products were
digested with AvaI and HindIII and were then
ligated into the polylinker of pMAL-c2 between the SalI and
HindIII sites. Direct cloning of some of the PCR
products into pMAL-c2 was unsuccessful; therefore, these products were initially cloned into a PCR cloning vector, pGEM-T (Promega). Ligation
and transformation of pGEM-T was carried out as described by the
manufacturer. The PCR products were excised from pGEM-T by restriction
digestion. The inserts were gel purified and ligated into the
polylinker of pMAL-c2 digested with the corresponding restriction
enzymes.
The recombinant pMAL/msg-b clones were sequenced by a modified
double-stranded DNA sequencing technique (Sequenase, version
2.0, U.S.
Biochemicals). A mutation was detected in
pMAL/msg-b
579-966.
A point mutation at bp 966 (T

A)
created a stop codon that resulted
in the expression of a fusion
protein that extends from amino
acids 193 to 322 with a predicted
molecular weight of 60,000 (
MBPMSG
193-322).
Analysis of the DNA sequence of pMAL/msg-b
375-576 revealed
following base 576 a frameshift mutation that altered
the MSG-B
amino acid sequence starting at amino acid 192 and that
created a stop
codon at base 709. Thus, the resulting fusion protein
had a predicted
molecular weight of 62,957, but the MSG-B amino
acid sequence extended
only from residues 125 to 192 (
MBPMSG
125-192).
The remaining six constructs were cloned in
the correct reading frame
with MBP and contained no mutations.
Fusion protein expression and purification.
The pMAL/msg-b
plasmids were used to transform electrocompetent Escherichia
coli in an Electroporator II apparatus (Invitrogen, San Diego,
Calif.) according to the manufacturer's instructions. Positive
transformants were picked and grown overnight at 37°C in 25-ml
cultures of Luria-Bertani liquid broth supplemented with 50 µg of
ampicillin per ml (LB-amp). On the following day, the overnight
cultures were used to inoculate new 1-liter cultures of LB-amp which
were then grown to an optical density at 600 nm (OD600) of
0.5 to 0.7. Fusion protein production was induced by the addition of
isopropyl-
-D-thiogalactopyranoside to a final concentration of 0.5 mM. After 3 h of induction at 37°C, the
cultures were centrifuged at 4,000 × g for 20 min and
bacterial pellets were reconstituted in 25 ml of amylose column buffer
(20 mM Tris-HCl [pH 7.0], 200 mM NaCl, 1 mM EDTA).
After freezing overnight at

20°C, cell suspensions were thawed and
sonicated for five cycles of 15-s bursts followed by 15
s on ice.
Sonicates were centrifuged at 10,000 ×
g for 30 min,
and
MBPMSG-B fusion proteins were purified from the
supernatants by using
an amylose resin column (New England Biolabs)
according to the
manufacturer's instructions.
SDS-PAGE and immunoblotting.
Proteins were solubilized in
2× lysis buffer (125 mM Tris-HCl [pH 6.8], 4.0% sodium dodecyl
sulfate (SDS), 20% glycerol, 10%
-mercaptoethanol) for analysis by
SDS-polyacrylamide gel electrophoresis (PAGE) (22, 25). The
proteins were transferred electrophoretically from the
SDS-polyacrylamide gel to a nitrocellulose membrane, and immunoblotting
was performed as described previously (25, 45).
ELISA.
Purified fusion proteins from the deletion constructs
were diluted to 20 µg/ml in coating buffer from the ELISAmate reagent kit (Kirkegaard & Perry), and 50 µl was used to sensitize 96-well polyvinyl ELISA plates (Dynatech, Chantilly, Va.) overnight at 4°C.
All subsequent steps were performed at room temperature. The wells were
washed twice with ELISAmate wash buffer and were blocked with ELISAmate
bovine serum albumin blocking reagent for 2 h. The wells were
washed four times with wash buffer, incubated with the MAb for 2 h, washed four times with wash buffer, and then incubated with goat
anti-mouse immunoglobulin G-horseradish peroxidase conjugated antibody
(Kirkegaard & Perry) at a 1:1,000 dilution in ELISAmate diluent buffer
for 2 h. The wells were washed four times in wash buffer and
developed with ELISAmate ABTS peroxidase substrate. The optical
densities of the wells were monitored at 405 nm on a 96-well plate
reader (Bio-Tek Instruments, Winooski, Vt.).
 |
RESULTS |
Assessment of MAb epitope prevalence in the MSG family.
A
panel of MAbs known to react with MSG had been generated previously
(27). To estimate the number of MSG isoforms recognized by
each of these MAbs, we used a genomic expression library that had been
made by insertion of random fragments from the P. carinii f.
sp. carinii genome into
gt11. A genomic expression
library could be used because previous studies had shown that MSG genes lack introns (41). It was determined that 4,000 to 5,000 plaques contain one genome equivalent in this library. However, because the inserts in the library are in random orientations and reading frames with respect to the vector DNA sequence, only one of six MSG
gene fragments would be expected to be capable of expressing an MSG
epitope. Therefore, 24,000 plaques would be expected to express every
unique epitope at least once.
Ten previously described MAbs (MAbs RA-F1, RB-E3, RA-C6, RB-C8, RB-F9,
HB-G6, RA-C7, RA-C1, RA-C11, and RB-F8) were each used
to screen
300,000 plaques in the expression library (
27). Table
1
shows that the number of reactive plaques ranged from three
positive
plaques with MAb HB-G6 to 738 positive plaques with MAb
RA-F1.
The plaque data suggested that MAb RA-F1 recognized an epitope found on
many MSGs. To examine this possibility, four RA-F1-reactive
clones were
chosen for further analysis. After plaque purification,
the insert size
was determined by
EcoRI digestion of the phage
DNA. The four
phages contained different inserts, which ranged
in size from 1.3 kb
(clone 2) to 4 kb (clone 1) (Fig.
1).
Analysis
of the DNA sequence showed that each clone contained a
different
MSG gene (data not shown).

View larger version (6K):
[in this window]
[in a new window]
|
FIG. 1.
Physical maps and MAb reactivities of four gt11
clones each carrying a fragment from a different MSG gene. The lines
show the sizes of the inserts carried in the four phage clones compared
to the size of a previously characterized cloned msg gene
(msg-b). The numbers at the ends of each line indicate the
amino acid residues encoded by each msg gene fragment. The
reactivity (+) or nonreactivity ( ) of the plaques produced by each
clone is indicated for each of eight MAbs.
|
|
To further characterize these RA-F1-positive phages, their reactivities
were assessed with the 11 other MAbs. Four of these
11 MAbs (MAbs
RA-C7, HB-G6, RA-C11, and RB-F8) did not react with
any of the clones,
which is consistent with the fact that each
of these four MAbs
recognized few plaques in the

gt11 library
screen (fewer than 23 plaques) (Table
1). The remaining seven
MAbs each reacted with at least
one RA-F1-positive phage (Fig.
1). Three MAbs (MAbs RA-F1, RA-E7, and
RA-G10) reacted with all
four clones, suggesting that they recognize
the same epitope,
and subsequent studies (described below) showed that
this was
the case. The reactivities of MAbs RA-F1, RA-E7, RA-G10,
RA-C1,
RA-C6, and RB-C8 with clone 2 indicates that the epitopes for
these MAbs are contained within the region from amino acids 227
to 660. The location of the epitopes for MAbs RB-E3 and RB-F9
could be
localized to the first 600 amino acids of MSG on the
basis of their
reactivities with clone 3.
Localization of two MSG-specific MAb epitopes.
To facilitate
identification of the MAb epitopes, the msg-b isoform
was produced in a bacterial expression system as described in
the Materials and Methods. The MBPMSG-B fusion protein
(MBPMSG-B41-1065) was assayed by immunoblot
analysis for its reactivity to the 12 MAbs (data not shown), and it was
found to be reactive with MAbs RA-F1, RA-E7, RA-G10, and RB-E3 (Fig.
1).
An epitope mapping strategy was designed to monitor the loss of
reactivity of the MAbs with truncated forms of the
MBPMSG-B
fusion protein. MAb RA-E7 was chosen to represent the RA-F1,
RA-E7, and
RA-G10 group because of the availability of sufficient
quantities of
this MAb for epitope mapping studies. RB-E3 was
selected because it
appeared to recognize a unique epitope. The
regions of MSG-B recognized
by MAbs RA-E7 and RB-E3 were initially
localized by expression of
truncated
MBPMSG-B fusion proteins produced by digestion of
pMAL/msg-b
124-3366 with ExoIII. MAbs RA-E7 and RB-E3
remained reactive with the two
shortest ExoIII-generated
truncations that stopped at MSG-B amino
acids 563 (
MBPMSG
41-563) and 373 (
MBPMSG-B
41-373) (Fig.
2 and
3,
lanes 3 and 4). These results
indicated that the epitopes were
contained in the region from
amino acids 41 to 373. Further attempts to
produce shorter proteins
by ExoIII digestion were unsuccessful.

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 2.
Mapping of MAb RA-E7 reactivity with MBPMSG
truncated fusion proteins by SDS-PAGE and immunoblotting. (A) Coomassie
blue-stained gel. (B) Immunoblot with anti-MBP polyclonal antisera. (C)
Immunoblot with RB-E7. Lanes 1, MBP; lanes 2, native MSG; lanes 3, MBPMSG41-561; lanes 4, MBPMSG41-373; lanes 5, MBPMSG41-324; lanes 6, MBPMSG41-290; lanes 7, MBPMSG41-278; lanes 8, MBPMSG193-322. (D) ELISA analysis of MAb RA-E7
reactivity with MBPMSG-B truncated fusion proteins. Wells
of 96-well microtiter plates were coated with the fusion proteins or
MBP alone. The numbers correspond to the lanes described above. (E)
Schematic of mapping of the epitope reactive with MAb RA-E7. The
numbers in parentheses correspond to the lanes described above.
|
|

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 3.
Mapping of MAb RB-E3 reactivity with MBPMSG
truncated fusion proteins by SDS-PAGE, immunoblotting, and ELISA. (A)
Coomassie blue-stained gel. (B) Immunoblot with anti-MBP polyclonal
antisera. (C) Immunoblot with RB-E3. Lanes 1, MBP; lanes 2, native MSG;
lanes 3, MBPMSG41-561; lanes 4, MBPMSG41-373; lanes 5, MBPMSG41-195; lanes 6, MBPMSG125-192; lanes 7, MBPMSG41-184; lanes 8, MBPMSG171-349. (D) ELISA analysis of MAb RB-E3
reactivity with MBPMSG-B truncated fusion proteins. Wells
of 96-well microtiter plates were coated with the fusion proteins or
MBP alone. The numbers correspond to the lanes described above. (E)
Schematic of mapping of the epitope reactive with MAb RB-E3. The
numbers in parentheses correspond to the lanes described above.
|
|
To identify the epitopes recognized by MAbs RB-E3 and RA-E7,
MBPMSG-B fusion proteins that covered amino acids 41 to 373 were
prepared by amplifying the target regions of
msg-b by
PCR and
cloning the products into pMAL-c2. Evaluation of the fusion
proteins
expressed from the PCR-generated pMAL/msg-b constructs by
SDS-PAGE
(Fig.
2A and
3A) and immunoblotting with polyclonal antisera
against
MBP (Fig.
2B and
3B) demonstrated that they were of the
predicted
size.
The epitope for RA-E7 was mapped to MSG-B amino acids 279 to 290 by
monitoring the loss of MAb reactivity of the fusion proteins
by
immunoblotting (Fig.
2C) and ELISA (Fig.
2D). The epitope was
deduced
from variations in reactivity between
MBPMSG
41-278 and
MBPMSG
41-290. The
MBPMSG
41-278 construct contains MSG-B
amino acids 41 to 278,
and
MBPMSG
41-290 covers
amino acids 41 to 290. The loss of reactivity
of MAb RA-E7 with
MBPMSG
41-278 identifies the reactive amino
acids as amino acids
279 to 290 (Fig.
2E). A construct with a large 5'
deletion (
MBPMSG
193-587) also reacted with MAb
RA-E7, indicating that
the upstream portion of MSG-B from amino acids
41 to 193 is not
required for recognition by MAb RA-E7. This finding
was also supported
by the reactivity of phage clone 2 with MAb RA-E7;
clone 2 contained
MSG amino acids 227 to 660 (Fig.
1). MAbs RA-G10 and
RA-F1 demonstrated
reactivity patterns with the truncated fusion
proteins identical
to that of MAb RA-E7, confirming that all three MAbs
recognize
the same epitope (data not shown).
MAb RB-E3 recognized all of the PCR-generated
MBPMSG-B fusion proteins except for
MBPMSG
41-184 by immunoblotting (Fig.
3C) and
ELISA (Fig.
3D).
Comparison of the nonreactive
MBPMSG
41-184 fusion protein and the reactive
MBPMSG
125-192 fusion protein demonstrated that
amino acids
185 to 192 are involved in the recognition of MSG-B by MAb
RB-E3
(Fig.
3E).
The reactivity of MAb RB-E3 with
MBPMSG
125-192
was not dependent on upstream amino acids 125 to 171, as demonstrated
by
the recognition of the
MBPMSG
171-349 fusion
protein by MAb RB-E3. The localization
of the reactivity of MAb RB-E3
to amino acids 184 to 192 is also
supported by the phage clone data,
which suggest that this epitope
is contained within the first 223 amino
acids of MSG-B (Fig.
1).
Analysis of the epitope regions in additional MSG isoforms.
The availability of reactive and nonreactive phages provided a means of
comparing the epitopes in these clones to the epitopes identified in
MSG-B. The regions corresponding to those encoding the epitope in MSG-B
reactive with MAbs RA-F1, RA-G10, and RA-E7 were amplified from phage
clones 2 and 4, both of which produced plaques that were reactive with
MAb RA-E7. The PCR products were cloned into pGEM-T, and the DNA was
sequenced. Analysis of the deduced amino acid sequence revealed that
the sequence of clone 2 matched the MSG-B sequence exactly and the
sequence of clone 4 matched at 10 of 11 of the MSG-B amino acids (Fig.
4A). This finding supports the idea that
the region reactive with MAb RA-E7 is highly conserved among MSG
isoforms. The 12-amino-acid binding site for MAb RA-E7 was also well
conserved among five additional MSG sequences predicted from previously
published DNA sequences (Fig. 4A). A similar analysis of the putative
epitope reactive with MAb RB-E3 yielded a more complex picture (Fig.
4B). While only clone 3 produced reactive phage plaques, the predicted
amino acid sequences of both clones 1 and 3 were similar to the MSG-B sequence, and within the epitope there were no obvious amino acid substitutions that may account for the variation of reactivity between
clones 1 and 3. Therefore, amino acids 185 to 192 appear to be
essential for the reactivity of MAb RB-E3 with MSG-B, but additional
amino-terminal residues may be involved in the presentation of the
epitope to the antibody.

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 4.
Alignment of MSG-B epitope region reactive with MAbs
RA-E7 and RB-E3 with seven additional deduced MSG amino acid sequences.
The deduced amino acid sequence of the epitope regions from five
previously described P. carinii f. sp. carinii
MSGs and from the four phage clones were visually aligned with the
MAb-reactive epitopes identified on MSG-B. (A) RA-E7 epitope; (B) RB-E3
epitope. a, from reference 48; b, from reference
21; c, deduced amino acids from gt11 clones.
|
|
 |
DISCUSSION |
The identification of conserved and variable epitopes on MSG
molecules provides a method of studying the expression of different isoforms through the use of either polyclonal antiserum produced against peptides or MSG-specific MAbs. Previously, three different MSG
variants were identified in a single lobe of an infected lung with
epitope-specific polyclonal antisera by immunohistochemistry (1). In another study two MSG-specific MAbs (MAbs RA-C6 and RA-C11) were able to identify antigenic differences between genetically distinct P. carinii f. sp. carinii and P. carinii f. sp. ratti populations and within a
genetically defined population of P. carinii f. sp.
carinii. Two additional MAbs (MAbs RA-F1 and RA-C7) reacted
with all P. carinii f. sp. carinii and P. carinii f. sp. ratti populations examined
(47).
In this study MSG-specific MAbs were initially characterized on the
basis of the frequency with which their epitopes are encoded within the
P. carinii f. sp. carinii genome by screening an
expression library made by insertion of randomly sheared genomic
P. carinii f. sp. carinii DNA. The MAbs could be
separated into four groups on the basis of the number of plaques that
each one recognized. MAb RA-F1 appeared to react with a conserved
epitope on the basis of its reactivity with 738 plaques. MAbs RB-E3,
RB-2F9, and RB-C8 each recognized between 100 and 300 plaques,
suggesting that these epitopes are encoded in multiple MSG genes. The
three MAbs in the third group (MAbs RA-C6, RA-C7, and RA-C1) reacted
with 46, 23, and 55 plaques, respectively. This group of MAbs appeared to recognize a less conserved epitope. The final group of MAbs (MAbs
HB-G6, RA-C11, and RB-F8) recognized a rare epitope on the basis of the
low number (three to seven) of plaques that they detected.
In addition to characterizing the frequency with which MAb epitopes are
expressed in the Pneumocystis genome, analysis of reactive
gt11 phage established that the MAbs react with MSG. Characterization of the MSG-specific MAbs was previously based on their
reactivity with a 116,000-molecular-weight glycoprotein that was
specific to Pneumocystis (27). The reactivities
of the MAbs with MSG were confirmed through DNA sequence analysis of
the
gt11 clones. The four reactive clones that were analyzed by DNA
sequencing all contained pieces of DNA that were homologous with
previously identified msg genes.
The reactivities of four MAbs with recombinant MSG provided a method
for mapping their epitopes. The epitope reactive with MAbs RA-F1,
RA-G10, and RA-E7 was localized to a highly conserved region in the
amino-terminal end of MSG-B and was identified as amino acids 278 to
290. Comparison of the identified epitope with deduced amino acids from
previously cloned msg genes, cDNAs, or cloned regions of MSG
from reactive
gt11 phage demonstrated that this sequence is highly
conserved. The reactivity of MAb RB-E3 was also localized in the
amino-terminal portion of MSG-B approximately 100 amino acids upstream
from the epitope reactive with MAbs RA-F1, RA-G10, and RA-E7. Amino
acids 185 to 192 of MSG-B were determined to be required for reactivity
with MAb RB-E3. Comparison of the amino acid sequence of the epitope
reactive with MAb RB-E3 with that of previously cloned msg
genes demonstrated that this region is not as well conserved as the
epitope reactive with MAbs RA-F1, RA-G10, and RA-E7. Alignment of the
amino acids in the RB-E3-reactive epitope regions from a reactive
gt11 phage and a nonreactive
gt11 phage did not reveal the
presence of critical residues that would be essential for reactivity.
There are two basic types of epitopes, continuous and discontinuous
(3, 46). Continuous epitopes consist of short linear sequences of amino acids. Discontinuous epitopes involve distant residues brought together by protein folding. The immunoblotting, ELISA, and sequence comparison data indicate that MSG-B amino acids 279 to 290 represent the epitope reactive with MAbs RA-F1, RA-G10, and
RA-E7, and deletion of these amino acids clearly results in the loss of
MAb reactivity. In addition, the high degree of conservation of the
epitope among other MSGs indicates that it is a continuous epitope. The
functional identification of the RB-E3-reactive epitope by
immunoblotting and ELISA suggests that it is continuous; however, the
lack of a correlation of MAb reactivity with the conservation of
specific amino acids indicates that additional residues may be required
for high-affinity binding of MAb RB-E3. The decreased reactivity
of the MBPMSG-B171-349 fusion protein
also indicates that additional amino acids removed from the epitope
region are required for antibody recognition. The presence of a
cysteine at residue 187 that could be involved in the folding of MSG
through the formation of disulfhydryl bonds is noteworthy. The location
of cysteine residues is maintained among all MSGs analyzed to date
(26, 52). The conservation of the cysteine positions
suggests the importance of disulfhydryl bonds in maintaining a
conserved higher-order structure that could be critical to the function
of MSG.
MSG has been implicated in the binding of P. carinii to host
cells and molecules. The extracellular MSG domains involved in these
interactions have not been identified, and little is known about the
position or orientation of MSG within the cell membrane or cell wall of
P. carinii. As described previously, MAbs RA-E7, RA-G10,
RA-F1, RB-E3, RA-C1, RA-C6, RB-C8, and RB-F9 react with the surface of
P. carinii f. sp. carinii by immunofluorescence (27). Localization of the MAb reactivity within the first
600 amino acids demonstrates that at least portions of the amino
terminus of MSG are exposed on the surface of P. carinii f.
sp. carinii. These results suggest that the surface-exposed
amino terminus of MSG may also be involved in binding to host proteins.
The presence of hundreds of MSG genes in the genome suggests that
P. carinii is capable of undergoing a form of antigenic variation and that the ability to alter this abundant surface protein
is critical to its survival. The MAbs characterized in these studies
will provide useful tools for analyzing the expression of particular
MSG isoforms on P. carinii.
 |
ACKNOWLEDGMENTS |
This work was supported by the Medical Research Service of the
U.S. Department of Veterans Affairs and Public Health Service contract
AI 25139 and grant AI 36701 from the National Institutes of Health.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: VA Medical
Center, 3200 Vine St., Cincinnati, OH 45220. Phone: (513) 861-3100, extension 4423. Fax: (513) 475-6415. E-mail: mjl19{at}juno.com.
 |
REFERENCES |
| 1.
|
Angus, C. W.,
A. Tu,
P. Vogel,
M. Qin, and J. A. Kovacs.
1996.
Expression of variants of the major surface glycoprotein of Pneumocystis carinii.
J. Exp. Med.
183:1229-1234[Abstract/Free Full Text].
|
| 2.
|
Ausubel, F. M.,
B. Brent,
R. E. Kingston,
D. D. Moore,
J. G. Seidman,
J. A. Smith, and K. Struhl (ed.).
1991.
Current protocols in molecular biology.
Greene Publishing Associates and Wiley-Interscience, New York, N.Y.
|
| 3.
|
Barlow, D. J.,
M. S. Edwards, and J. M. Thornton.
1986.
Continuous and discontinuous protein antigenic determinants.
Nature
322:747-748[Medline].
|
| 4.
|
Cushion, M. T.,
J. J. Ruffolo, and P. D. Walzer.
1988.
Analysis of the developmental stages of Pneumocystis carinii, in vitro.
Lab. Invest.
58:324-331[Medline].
|
| 5.
|
Cushion, M. T.,
J. Zhang,
M. Kaselis,
D. Giuntoli,
S. L. Stringer, and J. R. Stringer.
1993.
Evidence for two genetic variants of Pneumocystis carinii coinfecting laboratory rats.
J. Clin. Microbiol.
31:1217-1223[Abstract/Free Full Text].
|
| 6.
|
Doherty, T. M.,
R. J. Booth,
S. G. Love,
J. J. Gibson,
D. R. Harding, and J. D. Watson.
1989.
Characterization of an antibody-binding epitope from the 18-kDa protein on Mycobacterium leprae.
J. Immunol.
142:1691-1695[Abstract].
|
| 7.
|
Edman, J. C.,
T. W. Hatton,
M. Nam,
R. Turner,
Q. Mei,
C. W. Angus, and J. A. Kovacs.
1996.
A single expression site with a conserved leader sequence regulates variation of expression of the Pneumocystis carinii family of major surface glycoprotein genes.
DNA Cell Biol.
15:989-999[Medline].
|
| 8.
|
Edman, U.,
J. C. Edman,
B. Lundgren, and D. V. Santi.
1989.
Isolation and expression of the Pneumocystis carinii thymidylate synthase gene.
Proc. Natl. Acad. Sci. USA
86:6503-6507[Abstract/Free Full Text].
|
| 9.
|
Fisher, D. J.,
F. Gigliotti,
M. Zauderer, and A. G. Harmsen.
1991.
Specific T-cell response to a Pneumocystis carinii surface glycoprotein (gp120) after immunization and natural infection.
Infect. Immun.
59:3372-3376[Abstract/Free Full Text].
|
| 10.
|
Garbe, T. R., and J. R. Stringer.
1994.
Molecular characterization of clustered variants of genes encoding major surface antigens of human Pneumocystis carinii.
Infect. Immun.
62:3092-3101[Abstract/Free Full Text].
|
| 11.
|
Gigliotti, F.
1992.
Host species-specific antigenic variation of a mannosylated surface glycoprotein of Pneumocystis carinii.
J. Infect. Dis.
165:329-336[Medline].
|
| 12.
|
Gigliotti, F.,
L. R. Ballou,
W. T. Hughes, and B. D. Mosley.
1988.
Purification and initial characterization of a ferret Pneumocystis carinii surface antigen.
J. Infect. Dis.
158:848-854[Medline].
|
| 13.
|
Gigliotti, F.,
B. A. Garvy, and A. G. Harmsen.
1996.
Antibody-mediated shift in the profile of glycoprotein A phenotypes observed in a mouse model of Pneumocystis carinii pneumonia.
Infect. Immun.
64:1892-1899[Abstract].
|
| 14.
|
Gigliotti, F., and W. T. Hughes.
1988.
Passive immunoprophylaxis with specific monoclonal antibody confers partial protection against Pneumocystis carinii pneumonitis in animal models.
J. Clin. Invest.
81:1666-1668.
|
| 15.
|
Goldenberg, D. M.,
R. M. Sharkey,
S. Udem,
R. Vagg,
G. M. Levine,
P. Conte,
L. C. Swayne,
H. J. Hansen,
D. Cunniff,
J. Anton, et al.
1994.
Immunoscintigraphy of Pneumocystis carinii pneumonia in AIDS patients.
J. Nucl. Med.
35:1028-1034[Abstract/Free Full Text].
|
| 16.
|
Graves, D. C.,
S. J. McNabb,
M. H. Ivey, and M. A. Worley.
1986.
Development and characterization of monoclonal antibodies to Pneumocystis carinii.
Infect. Immun.
51:125-133[Abstract/Free Full Text].
|
| 17.
|
Graves, D. C.,
S. J. McNabb,
M. A. Worley,
T. D. Downs, and M. H. Ivey.
1986.
Analyses of rat Pneumocystis carinii antigens recognized by human and rat antibodies by using Western immunoblotting.
Infect. Immun.
54:96-103[Abstract/Free Full Text].
|
| 18.
|
Haidaris, P. J.,
T. W. Wright,
F. Gigliotti, and C. G. Haidaris.
1992.
Expression and characterization of a cDNA clone encoding an immunodominant surface glycoprotein of Pneumocystis carinii.
J. Infect. Dis.
166:1113-1123[Medline].
|
| 19.
|
Kovacs, J. A.,
J. L. Halpern,
B. Lundgren,
J. C. Swan,
J. E. Parrillo, and H. Masur.
1989.
Monoclonal antibodies to Pneumocystis carinii: identification of specific antigens and characterization of antigenic differences between rat and human isolates.
J. Infect. Dis.
159:60-70[Medline].
|
| 20.
|
Kovacs, J. A.,
J. L. Halpern,
J. C. Swan,
J. Moss,
J. E. Parrillo, and H. Masur.
1988.
Identification of antigens and antibodies specific for Pneumocystis carinii.
J. Immunol.
140:2023-2031[Abstract/Free Full Text].
|
| 21.
|
Kovacs, J. A.,
F. Powell,
J. C. Edman,
B. Lundgren,
A. Martinez,
B. Drew, and C. W. Angus.
1993.
Multiple genes encode the major surface glycoprotein of Pneumocystis carinii.
J. Biol. Chem.
268:6034-6040[Abstract/Free Full Text].
|
| 22.
|
Laemmli, U. K.
1970.
Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
Nature
227:680-685[Medline].
|
| 23.
|
Lee, C. H.,
C. D. Bolinger,
M. S. Bartlett,
R. B. Kohler,
C. E. Wilde III, and J. W. Smith.
1986.
Production of monoclonal antibody against Pneumocystis carinii by using a hybrid of rat spleen and mouse myeloma cells.
J. Clin. Microbiol.
23:505-508[Abstract/Free Full Text].
|
| 24.
|
Linder, E.,
L. Lundin, and H. Vorma.
1987.
Detection of Pneumocystis carinii in lung-derived samples using monoclonal antibodies to an 82 kDa parasite component.
J. Immunol. Methods
98:57-62[Medline].
|
| 25.
|
Linke, M. J.,
M. T. Cushion, and P. D. Walzer.
1989.
Properties of the major antigens of rat and human Pneumocystis carinii.
Infect. Immun.
57:1547-1555[Abstract/Free Full Text].
|
| 26.
|
Linke, M. J.,
A. G. Smulian,
J. R. Stringer, and P. D. Walzer.
1994.
Characterization of multiple unique cDNAs encoding the major surface glycoprotein of rat-derived Pneumocystis carinii.
Parasitol. Res.
80:478-486[Medline].
|
| 27.
|
Linke, M. J.,
A. G. Smulian,
P. Yoshihara, and P. D. Walzer.
1994.
Production and characterization of monoclonal antibodies specific for the major surface glycoprotein of Pneumocystis carinii.
J. Eukaryot. Microbiol.
41:99S-100S[Medline].
|
| 28.
|
Lundgren, B.,
M. Lebech,
K. Lind,
J. O. Nielsen, and J. D. Lundgren.
1993.
Antibody response to a major human Pneumocystis carinii surface antigen in patients without evidence of immunosuppression and in patients with suspected atypical pneumonia.
Eur. J. Clin. Microbiol. Infect. Dis.
12:105-109[Medline].
|
| 29.
|
Matsumoto, Y.,
T. Amagai,
M. Yamada,
J. Imanishi, and Y. Yoshida.
1987.
Production of a monoclonal antibody with specificity for the pellicle of Pneumocystis carinii by hybridoma.
Parasitol. Res.
73:228-233[Medline].
|
| 30.
|
O'Riordan, D. M.,
J. E. Standing, and A. H. Limper.
1995.
Pneumocystis carinii glycoprotein A binds macrophage mannose receptors.
Infect. Immun.
63:779-784[Abstract].
|
| 31.
|
Peglow, S. L.,
A. G. Smulian,
M. J. Linke,
C. L. Pogue,
S. Nurre,
J. Crisler,
J. Phair,
J. W. Gold,
D. Armstrong, and P. D. Walzer.
1990.
Serologic responses to Pneumocystis carinii antigens in health and disease.
J. Infect. Dis.
161:296-306[Medline].
|
| 32.
|
Pneumocystis Working Group.
1994.
Nomenclature of Pneumocystis.
J. Eukaryot. Microbiol.
41:121S-122S[Medline].
|
| 33.
|
Pottratz, S. T.,
J. Paulsrud,
J. S. Smith, and W. J. Martin, II.
1991.
Pneumocystis carinii attachment to cultured lung cells by pneumocystis gp 120, a fibronectin binding protein.
J. Clin. Invest.
88:403-407.
|
| 34.
|
Radding, J. A.,
M. Y. Armstrong,
E. Ullu, and F. F. Richards.
1989.
Identification and isolation of a major cell surface glycoprotein of Pneumocystis carinii.
Infect. Immun.
57:2149-2157[Abstract/Free Full Text].
|
| 35.
|
Roths, J. B., and C. L. Sidman.
1993.
Single and combined humoral and cell-mediated immunotherapy of Pneumocystis carinii pneumonia in immunodeficient scid mice.
Infect. Immun.
61:1641-1649[Abstract/Free Full Text].
|
| 36.
|
Sambrook, J.,
E. F. Fritsch, and T. Maniatis.
1989.
Molecular cloning: a laboratory manual, 2nd ed.
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 37.
|
Smulian, A. G.,
S. A. Theus,
N. Denko,
P. D. Walzer, and J. R. Stringer.
1993.
A 55 kDa antigen of Pneumocystis carinii: analysis of the cellular immune response and characterization of the gene.
Mol. Microbiol.
7:745-753[Medline].
|
| 38.
|
Stringer, S. L.,
S. T. Hong,
D. Giuntoli, and J. R. Stringer.
1991.
Repeated DNA in Pneumocystis carinii.
J. Clin. Microbiol.
29:1194-1201[Abstract/Free Full Text].
|
| 39.
|
Sunkin, S. M., and J. R. Stringer.
1996.
Translocation of surface antigens to a unique telomeric expression site in Pneumocystis carinii.
Mol. Microbiol.
19:283-295[Medline].
|
| 40.
|
Sunkin, S. M., and J. R. Stringer.
1995.
Transcription factor genes from rat Pneumocystis carinii.
J. Eukaryot. Microbiol.
42:12-19[Medline].
|
| 41.
|
Sunkin, S. M.,
S. L. Stringer, and J. R. Stringer.
1994.
A tandem repeat of rat-derived Pneumocystis carinii genes encoding the major surface glycoprotein.
J. Eukaryot. Microbiol.
41:292-300[Medline].
|
| 42.
|
Tanabe, K.,
S. Takasaki,
J. Watanabe,
A. Kobata,
K. Egawa, and Y. Nakamura.
1989.
Glycoproteins composed of major surface immunodeterminants of Pneumocystis carinii.
Infect. Immun.
57:1363-1368[Abstract/Free Full Text].
|
| 43.
|
Theus, S. A.,
R. P. Andrews,
P. Steele, and P. D. Walzer.
1995.
Adoptive transfer of lymphocytes sensitized to the major surface glycoprotein of Pneumocystis carinii confers protection in the rat.
J. Clin. Invest.
95:2587-2593.
|
| 44.
|
Theus, S. A.,
M. J. Linke,
R. P. Andrews, and P. D. Walzer.
1993.
Proliferative and cytokine responses to a major surface glycoprotein of Pneumocystis carinii.
Infect. Immun.
61:4703-4709[Abstract/Free Full Text].
|
| 45.
|
Towbin, H.,
T. Staehelin, and J. Gordon.
1979.
Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.
Proc. Natl. Acad. Sci. USA
76:4350-4354[Abstract/Free Full Text].
|
| 46.
|
VanRegenmortel, M.
1989.
Structural and functional approaches to the study of protein antigenicity.
Immunol. Today
10:266-272[Medline].
|
| 47.
|
Vasquez, J.,
A. G. Smulian,
M. J. Linke, and M. T. Cushion.
1996.
Antigenic differences associated with genetically distinct Pneumocystis carinii from rats.
Infect. Immun.
64:290-297[Abstract].
|
| 48.
|
Wada, M.,
K. Kitada,
M. Saito,
K. Egawa, and Y. Nakamura.
1993.
cDNA sequence diversity and genomic clusters of major surface glycoprotein genes of Pneumocystis carinii.
J. Infect. Dis.
168:979-985[Medline].
|
| 49.
|
Wada, M.,
S. M. Sunkin,
J. R. Stringer, and Y. Nakamura.
1995.
Antigenic variation by positional control of major surface glycoprotein gene expression in Pneumocystis carinii.
J. Infect. Dis.
171:1563-1568[Medline].
|
| 50.
|
Walzer, P. D., and M. J. Linke.
1987.
A comparison of the antigenic characteristics of rat and human Pneumocystis carinii by immunoblotting.
J. Immunol.
138:2257-2265[Abstract].
|
| 51.
|
Wernke, G. (Cincinnati, Ohio)
1988.
DNANALYZE, version 5.2
.
|
| 52.
|
Wright, T. W.,
P. J. Simpson-Haidaris,
F. Gigliotti,
A. G. Harmsen, and C. G. Haidaris.
1994.
Conserved sequence homology of cysteine-rich regions in genes encoding glycoprotein A in Pneumocystis carinii derived from different host species.
Infect. Immun.
62:1513-1519[Abstract/Free Full Text].
|
| 53.
|
Zhang, J., and J. R. Stringer.
1993.
Cloning and characterization of an alpha-tubulin-encoding gene from rat-derived Pneumocystis carinii.
Gene
123:137-141[Medline].
|
| 54.
|
Zimmerman, P. E.,
D. R. Voelker,
F. X. McCormack,
J. R. Paulsrud, and W. J. Martin, II.
1992.
120-kD surface glycoprotein of Pneumocystis carinii is a ligand for surfactant protein A.
J. Clin. Invest.
89:143-149.
|
Clinical and Diagnostic Laboratory Immunology, January 1998, p. 50-57, Vol. 5, No. 1
1071-412X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Cushion, M. T., Keely, S. P., Stringer, J. R.
(2004). Molecular and phenotypic description of Pneumocystis wakefieldiae sp. nov., a new species in rats. Mycologia
96: 429-438
[Abstract]
[Full Text]
-
Schaffzin, J. K., Stringer, J. R.
(2004). Expression of the Pneumocystis carinii major surface glycoprotein epitope is correlated with linkage of the cognate gene to the upstream conserved sequence locus. Microbiology
150: 677-686
[Abstract]
[Full Text]
-
Walzer, P. D.
(1999). Immunological Features of Pneumocystis carinii Infection in Humans. CVI
6: 149-155
[Full Text]